Practice Update · Published August 1, 2026
Big news from the FDA on peptide therapy.
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee held a two-day meeting devoted to peptide medicine and voted in favor of six peptides, several of them among the most established names in regenerative care. Here is what happened, what it means, and just as importantly, what it does not mean yet.
Looking for our July practice update? It is preserved below ↓
The FDA's advisory committee backed six peptides.
The Pharmacy Compounding Advisory Committee (PCAC) is the independent panel of physicians, pharmacists, and scientists that advises the FDA on compounding policy. At its July meeting, the committee reviewed seven peptides nominated for the 503A bulk substances list, the official list of ingredients that state-licensed compounding pharmacies are permitted to compound with. It was the committee's most significant peptide-focused meeting since the FDA's 2023 reclassification narrowed which peptides pharmacies could work with.
The results, peptide by peptide:
Day One · July 23 · Split Votes in Favor
Day Two · July 24 · Split Votes
Votes recommend adding each peptide to the FDA's 503A bulk substances list. All six favorable votes were split, not unanimous; the day-one peptides passed 8–6 (MOTS-c 7–5), each with abstentions. Vote counts as reported in trade coverage of the meeting; see sources below.
The discussion was not one-sided. FDA scientific staff raised concerns during the meeting, including limited published efficacy data for some nominations and questions about peptide impurities. The committee majority weighed those concerns against the view that licensed prescribers and pharmacists are positioned to judge suitability for individual patients. Both perspectives are part of the record the FDA will now consider.
A meaningful step, not a finish line.
Advisory committee votes are recommendations, not law. The FDA is not required to follow them, and nothing has legally changed yet: the agency will now weigh the committee's recommendations, the public docket comments, and its own scientific review before issuing final determinations. No timeline has been announced for that decision.
Still, the direction matters. A favorable vote from the FDA's own advisory panel is the first formal recognition of clinical need for these peptides in the compounding framework. If the FDA adopts the recommendations, peptides like BPC-157, KPV, TB-500, and MOTS-c would earn a durable, explicitly recognized place on the list of substances that state-licensed 503A pharmacies may compound, the same regulated pharmacy pathway Vesta has always used. And this was only round one: the committee is expected to meet again in early 2027 to review five additional peptides.
Familiar names, for good reason.
If you are a Vesta patient, several of the peptides on the committee's list will sound familiar: BPC-157, TB-500, KPV, MOTS-c, and Epithalon are all names from the world of regenerative and metabolic peptide care that our practice works in every day. Nothing about your care changes as a result of this meeting. Vesta's model is the same as it was last month: therapies are prescribed by a licensed provider after a consultation and labs where appropriate, and sourced exclusively through regulated, state-licensed 503A compounding pharmacies. Read more about that standard in our 503A promise.
What this news does change is the conversation. Peptide therapy has spent years in a regulatory gray zone that made honest patient education harder than it should be. A formal, public, on-the-record review by the FDA's own advisory committee, with favorable votes for six peptides, moves that conversation into the open, and it validates something we have long believed: that the right way to do peptide medicine is with provider oversight and regulated pharmacies, not gray-market vials sold online as "research use only." If you are curious what provider-led peptide therapy looks like, start with our peptide therapy overview or our guide to choosing a peptide clinic.
The GLP-1 compounding proposal moved one step forward.
Separately, July 30, 2026 marked the close of the public comment period on the FDA's April proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. That proposal concerns large-scale 503B outsourcing facilities that compound from bulk ingredients. It does not change what a state-licensed 503A pharmacy may compound for an individual patient under a valid, patient-specific prescription, which is the only model Vesta has ever used. The FDA will now review the submitted comments before issuing a final determination; no decision date has been announced.
For the full plain-English breakdown of what is and is not allowed in GLP-1 compounding, including the questions every patient should ask any provider, see our guide: Is Compounded Semaglutide Legal in 2026?
Sources for this update
FDA, Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026 · Regulatory Focus (RAPS), committee vote report · Mintz, legal analysis of the votes · FDA, April 30, 2026 GLP-1 proposal. This update is educational and is not medical or legal advice.
A lot is changing. Here is all of it, clearly.
Our July practice update remains in full below for easy reference. Over the past year Vesta has grown more than we ever imagined, and that growth made these changes necessary. Many of them began as requests from patients like you. New phone number, Idaho expansion, expanded memberships, couples plans, a bigger referral program, and more treatment options: it is all here.
We upgraded our phone system.
Our practice outgrew the phone setup we started with. To keep up with the volume of calls and texts we now receive every day, and in response to patient feedback asking for easier, more reliable ways to reach us, we moved to a dedicated business line.
Our New Phone Number
Calls and texts welcome. Please save it in your contacts as Vesta Aesthetics.
There is no rush and nothing to worry about: our old number will remain active for the next 12 months, so if you call or text it you will still reach us. Going forward, though, the new number is the best and fastest way to get in touch.
Vesta is now serving Idaho.
In addition to serving patients throughout Utah and Arizona, we now provide telehealth care to patients in Idaho as well. This expansion, one of our most requested, brings our approach to wellness, weight loss, hormone optimization, peptide therapies, and aesthetics to even more patients throughout the region.
And we are not stopping at three states. As demand grows, we are actively evaluating expansion into additional surrounding states. If there is a state you would like to see us serve, request it here; so many of the improvements on this page began as suggestions from patients just like you.
Expanded memberships.
Over the past couple of months we have rolled out additional membership lengths and terms, many of them added directly at the request of our patients. Every membership includes provider oversight and individualized treatment planning, telehealth consultations, direct provider messaging, lab coordination, premium medication pricing with savings of up to 40% compared to a la carte, larger vial sizes when clinically appropriate, and 10% off aesthetic services.
- Up to two free follow-up visits per month, a members-only benefit, available whenever you feel they are needed
- Only one follow-up visit is required every three months to maintain active prescriptions and ensure safe ongoing treatment, in line with industry standards for medications of all kinds
Individual Membership
Couples Membership (per person)
All memberships may also be paid in full for an additional 10% discount.
New to couples memberships: health goals are easier to reach with support and accountability from someone important in your life. Couples receive additional savings with the same level of provider oversight, and when clinically appropriate and desired by both patients, couples may complete follow-up visits together. Full details on the memberships page.
Your current program is not going away.
You may choose to remain on your current program or transition to one of our membership options. The choice is entirely yours. We are not requiring anyone to move to a membership, though many patients find significant value in the added benefits, flexibility, and savings.
A special thank-you for existing patients
Anyone transitioning from a current treatment plan to a membership receives our 12-month membership rate regardless of term: individual memberships at $99/month and couples memberships at $89/month per person, whether you choose 3, 6, or 12 months. Many patients find the membership math works out the same as or better than what they pay today, while unlocking every membership benefit. We will gladly walk through your exact numbers at your next visit.
More medication & peptide options.
One of the most exciting developments is the significant expansion of our treatment options. In addition to our existing weight loss programs, we now offer a much broader range of wellness therapies, hormone optimization support, and peptide treatments through our growing network of trusted 503A compounding pharmacy partners. Many of these therapies were added because patients asked for them by name.
Unlike products commonly marketed online as "research use only" or sourced through unregulated gray-market channels, everything offered through Vesta is prescribed and medically managed by a licensed healthcare provider and sourced through regulated 503A compounding pharmacies operating under federal and state quality standards. Read more in our 503A promise.
A bigger referral program.
When a brand-new patient enrolls using your referral, you both win. Your friend receives a $25 credit toward their first purchase, and you earn account credit based on what they choose: $25 for an eligible a la carte purchase of $100 or more or a 3-month membership, $50 for a 6-month membership, and $100 for a 12-month membership.
- Referral credits stack, with no limit on how many referrals you can earn credit for
- A referred couple counts as two referrals: both on 12-month plans earns you $200 ($100 per person)
- Credits can be spent on medications, peptide therapies, aesthetic services, and membership renewals
- Credits are valid for 12 months and cannot be applied to enrollment costs or laboratory services
Full details and terms on the referral program page.
Laboratory testing.
Laboratory testing is ordered only when clinically appropriate and is billed separately. Lab work is processed through independent third-party laboratories such as LabCorp and Quest Diagnostics. Because these are third-party services, Vesta does not control laboratory pricing and cannot apply referral credits or discounts toward laboratory costs.
Thank you for growing with us.
This past year of growth happened because you trusted us with your care and told the people you love about us. None of these improvements would exist without you.
Explore the New MembershipsAvailability updates & treatment insights
Subscribe for availability updates, announcements, and treatment insights. For Utah, Arizona & Idaho patients, unsubscribe any time.
Deciding between medications? Semaglutide vs tirzepatide, compared →
Your plan starts with a $75 initial consultation
Meet one-on-one with Ali Claunch, NP-C through a HIPAA compliant telehealth consultation. We review your goals, health history, and labs, then build a personalized treatment plan. Caring for patients across Utah, Arizona, and Idaho, with in-clinic visits in Saratoga Springs.
Follow-up visits are included with an active membership. À la carte patients schedule a $75 follow-up consult at least every 90 days while on therapy.
Schedule a ConsultationA Note on Compounded Medications and FDA Oversight
Compounded peptides, GLP-1 medications, hormone therapies, NAD+ preparations, and other prescription items dispensed through Vesta Aesthetics are prepared by licensed 503A compounding pharmacies for individual patients pursuant to a valid prescription from Ali Claunch, NP-C, following a personalized clinical evaluation. Compounded medications are not FDA-approved. The FDA does not evaluate compounded preparations for safety, efficacy, or potency. Vesta Aesthetics operates in compliance with FDA regulations governing 503A patient-specific compounding and does not stock, resell, or distribute medications outside this framework. If the FDA changes guidance, restricts, or removes access to any compounded preparation, Vesta will discontinue that preparation in alignment with federal regulation.
Information on this site is educational and is not a substitute for individualized medical advice, diagnosis, or treatment. Outcomes vary by patient. No specific clinical result is promised or guaranteed. Use of any prescription medication carries risk; please review all risks with your provider before beginning therapy. Vesta Aesthetics is a self-pay medical practice and does not bill insurance. See our 503A Promise for full sourcing detail.